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Abstract
Background: Variant Creutzfeldt–Jakob disease (vCJD) is a prion disease thought to be acquired by the consumption of
prion-contaminated beef products. To date, over 200 cases have been identified around the world, but mainly in the United
Kingdom. Three cases have been identified in the United States; however, these subjects were likely exposed to prion
infection elsewhere. Here we report on the first of these subjects.
Methodology/Principal Findings: Neuropathological and genetic examinations were carried out using standard
procedures. We assessed the presence and characteristics of protease-resistant prion protein (PrP
res) in brain and 23
other organs and tissues using immunoblots performed directly on total homogenate or following sodium
phosphotungstate precipitation to increase PrP
res detectability. The brain showed a lack of typical spongiform degeneration
and had large plaques, likely stemming from the extensive neuronal loss caused by the long duration (32 months) of the
disease. The PrP
res found in the brain had the typical characteristics of the PrP
res present in vCJD. In addition to the brain
and other organs known to be prion positive in vCJD, such as the lymphoreticular system, pituitary and adrenal glands, and
gastrointestinal tract, PrP
res was also detected for the first time in the dura mater, liver, pancreas, kidney, ovary, uterus, and
skin.
Conclusions/Significance: Our results indicate that the number of organs affected in vCJD is greater than previously
realized and further underscore the risk of iatrogenic transmission in vCJD.
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Introduction
Variant Creutzfeldt-Jakob disease (vCJD) was first reported in
1996 as a novel non-inherited form of prion disease [1]. Although
the disease bears some of the classical features of the sporadic form
of the human transmissible spongiform encephalopathies (TSE) or
prion diseases, it has distinctive features [2–4]. Most remarkably,
vCJD presents at an average age of 26 years [4]; histopatholog-
ically is characterized by the presence of plaques containing prion
protein surrounded by vacuoles referred to as ‘‘florid’’ or ‘‘daisy’’
plaques [1]. Furthermore, the abnormal and pathogenic prion
protein isoform (hereafter identified as PrP
res) associated with
vCJD has features that are unique among non-inherited human
prion diseases [5]. PrP
res is thought to be the major or lone
component of the infectious agent of prion disease, the so called
‘‘prion’’. However, occasionally not direct correlation has been
reported between PrP
res and infectivity [6].
The distinctive features of vCJD, along with its detection in the
UK following the peak of the British epidemic of the prion disease
bovine spongiform encephalopathy (BSE), pointed to the con-
sumption of prion-contaminated beef products as the possible
source of infection [1,7]. Successful transmission to non-human
primates and transgenic mice expressing the human prion protein
(human PrP) with replication of major features of the vCJD
phenotype, provided overwhelming evidence supporting the
notion of cattle-to-human transmission [8–10]. These findings
established vCJD as the first Western world prion disease to be
acquired by oral infection. Kuru, discovered in the 1950s, was
endemic among New Guinea tribes practicing ritualistic canni-
balism [11–13].
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8765The oral route of prion infection in vCJD raised the possibility
that tissues and organs, beside the central nervous system (CNS),
might also be affected. To date, PrP
res has been reported in several
tissues and organs outside the CNS of vCJD patients (Table 1)
[14–19, P. Brown, unpublished data].
Although the amount of PrP
res in non-neural tissues is small
compared to that in the brain, the risk posed by the spread of even
small amounts of PrP
res has been underscored by the iatrogenic
transmission of vCJD from blood donors in the preclinical phase of
the disease [20].
We examined the main characteristics and tissue distribution of
PrP
res in a case of vCJD, in which the disease was most likely
acquired in the UK but which is officially referred to as an
American case because illness onset occurred in the US [21]. In an
extensive autopsy examination, sodium phosphotungstate (NaPTA)
precipitation, a highly sensitive method of PrP
res detection [14,22],
was used to establish the presence and estimate the relative amounts
of PrP
resinseveral organsand tissues made available to the National
Prion Disease Pathology Surveillance Center (NPDPSC).
Materials and Methods
Collection and Processing of Tissues
A whole body autopsy was performed within 20 hours from
death. The National Prion Disease Pathology Surveillance Center
(NPDPSC) received frozen and fixed tissue samples. Frozen tissue
included slices from one cerebral and cerebellar hemisphere,
portions of pituitary gland and dura mater as well as samples from
the trachea, breast, heart, lung, esophagus, stomach, duodenum,
jejunum, ileum, colon, liver, spleen, pancreas, adrenal gland,
kidney, urinary bladder, uterus, ovary, mesenteric lymph nodes,
diaphragm and skin. The skin was taken from the chest wall. In
addition, paraffin blocks or sections from the same tissues were
also received. Frozen tissues were stored at 280uC.
Histopathology and Prion Protein Immunohistochemistry
Histology and immunohistochemistry were carried out as
previously described [23] on brain sections from frontal, temporal
and parietal neocortices (the occipital cortex was unavailable), neo-
striatum, thalamus, cerebellar hemisphere and on sections from all
received tissues. Immunohistochemistry was carried out with the
monoclonal antibody 3F4 to the PrP residues 109–112 [24].
Genetic Analysis
Genotyping was performed on genomic DNA extracted from
blood as previously described [25].
Preparation of Tissue Homogenates
Tissue homogenates (TH) (10%, wt/vol) were prepared at 4uC
in phosphate buffered saline (PBS) lacking Ca
2+ and Mg
2+,1 %
Sarkosyl (pH 7.4), followed by centrifugation at 10006g for 5
minutes to remove cellular debris. Excess of collagen was
eliminated by homogenizing tissue and removing the white and
dense fraction containing mainly collagen from the fraction rich in
parenchymal tissue. Contamination of non-nervous tissue with
brain tissue that might have occurred at autopsy was controlled by
sampling the depth of the organs and discarding the tissue at the
surface. Dura mater where this procedure was unsuitable was
rinsed extensively with PBS before homogenization.
Sodium Phosphotungstate Precipitation (NaPTA)
Precipitation with NaPTA was carried out according to Wads-
worth et al [14] with minor modifications. Briefly, 100 mg of wet
tissue were homogenized (10% wt/vol) with PBS lacking Ca
2+ and
Mg
2+, 2% Sarkosyl (pH 7.4), followed by centrifugation at 10006g
for 5 minutes to remove cellular debris. A fraction of the
supernatant was collected and frozen for immunoblot analysis,
whereas a second fraction of 500 ml was mixed with an equal
volume of PBS prepared as above. Samples were adjusted to a final
concentration of 50 units/ml ofBenzonaseand 1 mM of MgCl2 and
incubated at 37uC for 30 minutes, followed by the addition of
81.3 ml of a pre-warmed solution containing 4% NaPTA and
170 mM MgCl2. After incubation for another 30 minutes at 37uC
andconstant agitation, sampleswerecentrifuged at16,0006g for30
minutes. The supernatant was discarded whereas the pellet was re-
suspended in 200 ml of PBS containing 0.1% Sarkosyl (pH 7.4) with
theadditionof50 mlEDTA250 mM(pH 8),inordertoremovethe
white precipitate present in solution. After an additional centrifu-
gation at 16,0006g for 30 minute, supernatants were discarded and
the pellets re-suspended in 30 ml of PBS containing 0.1% Sarkosyl.
Immunoblot. Aliquots of TH or NaPTA-precipitated samples
were either examined untreated or after treatment for 1 hour at 37uC
with proteinase K (PK) (specific activity 44 units(U)/mg, Sigma
Aldrich) at the concentration of 2 U/ml (1 U/ml corresponds to
23 mg/ml when PK specific activity is 44 U/mg) for 60 minutes at
37uC while constantly agitated. The reaction was terminated by
addition of 3 mM of phenylmethylsulfonyl fluoride. Samples were
diluted in sample buffer (final concentration: 3% sodium dodecyl
sulfate [SDS], 4% ß-mercaptoethanol, 10% glycerol, 2 mM EDTA,
62.5 mM Tris, pH 6.8) and boiled for 10 minutes before loading. For
deglycoyslation of the protein, samples were denatured and incubated
in the presence of recombinant peptide N glycosidase F (PNGase F)
according to the manufacturer’s protocol (New England Biolabs).
Protein samples were separated in 15% Tris-Glycine SDS-PAGE gels
using gel electrophoresis apparatus holding running gels of different
lengths (Criterion 7 cm and home made 15 cm high-resolution system,
Bio-Rad). Proteins were transferred to Immobilon P (Millipore) for 2 h
at 65 V, blocked in 5% (w/v) non-fat milk powder in TBS containing
0.1% (v/v) Tween-20 (TBST) (blocking solution), and incubated
overnight at 4uC with selected antibodies. After several washes in
TBST, membranes where incubated with a 1:4,000 dilution of a
peroxidase-conjugated secondary antibody in TBST for 60 minutes at
room temperature, washed in TBST and visualized by enhanced
chemiluminescence (Amersham ECL Plus, GE Healthcare) on Kodak
BioMax XAR films (Eastman Kodak). Two antibodies to human PrP
were used: the monoclonal antibody 3F4 (to residues 109–112) and the
rabbit antisera 2301 (to residues 220–231).
Table 1. Peripheral tissues shown to contain PrP
res in vCJD
1.
Adrenal gland Pituitary gland
Appendix Rectum
Autonomic ganglia Retina
Blood vessels Skeletal muscle
Colon Spinal ganglia
Ileum Spleen
Jejunum Thymus
Lymph nodes Tonsil
Optic nerve Trigeminal ganglia
Peripheral nerves
1Data obtained from immunoblotting and immunohistochemistry studies.
Brown P., unpublished data; WHO Expert Committee Meeting, Baden, Austria,
18 May 2007 (updated through Jan 2009).
doi:10.1371/journal.pone.0008765.t001
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Results
Clinical History
Clinical data on the present patient have been reported in detail
[21]. Briefly, the patient lived in Britain until the age of 13 and
immigrated to the US in 1992. In early November 2001, at the age
of 22 years, the patient was evaluated for depression, emotional
instability and memory loss, followed one month later by
involuntary movements, gait disturbances and incontinence.
During the ensuing three months, the patient’s motor and
cognitive deficits worsened, and confusion, hallucination, dysar-
thria, bradykinesia, and spasticity also occurred. The diagnosis of
vCJD was made following brain magnetic resonance imaging and
confirmed by immunoblot and immunohistochemistry of tonsil
tissue. She received an experimental treatment with quinacrine for
3 months, but showed only minimal and transitory improvement.
The patient died in June 2004, 32 months after the clinical onset.
Histopathological Examination
Both gray and white matter structures were severely atrophic
with nearly total loss of neurons and replacement of the neuropil
with prominent gemistocytic astrogliosis (Fig. 1A and B). Thus, the
typical spongiform degeneration was not observed. Instead, there
were irregular extracellular spaces consistent with the astroglial
scarring present in the cerebral cortex (Fig. 1B). Macrophages
were also present occasionally, especially in the white matter, and
probably reflected Wallerian degeneration. The cerebral and
cerebellar cortices and the basal ganglia were more affected than
the thalamus. Many mono-centric plaques, often large and
occasionally surrounded by ‘‘pseudo vacuoles’’, were present
preferentially in the deep cerebral cortex and superficial white
matter as well as, to a lesser extent, in the cerebellar cortex and
white matter (Fig. 1B). All the organs that had been examined (see
Material and Methods for details) were unremarkable except for
the kidney and the descending colon which evidenced lymphocytic
inflammatory infiltrates (data not shown). In the kidney the
infiltrates displayed a focal follicular pattern consistent with
interstitial nephritis whereas in the descending colon the
lymphocytic infiltrates were linear and located in the sub-mucosa.
Immunohistochemical staining for PrP of brain sections
revealed numerous well circumscribed as well as more diffuse
PrP deposits consistent with unicentric plaques or early plaques
(also called plaque-like) formations, which were especially
prominent in the very superficial and deep cortical layers
(Fig. 1C and D). Granular and ‘‘synaptic’’ immunostaining
patterns were easily detectable in basal ganglia and thalamus.
The cerebellum showed a leopard skin-like immunostaining and
plaque-like patterns in the molecular and granule cell layer,
respectively (Fig. 1E and F). Polarized light examination confirmed
that the plaques contained amyloid (data not shown). No PrP
immunostaining was detected in any of the tissues examined
outside the brain.
Genetic analysis demonstrated methionine homozygosity at
codon 129 and no mutations or other variations in the open
reading frame of the PrP gene.
Characterization of Brain PrP
Immunoblot analyses of the PK-digested total homogenate (TH)
from all cerebral cortices examined displayed the characteristic
electrophoretic mobility and glycoform ratios of the PrP
res
described in vCJD (Fig. 2A) [5,26]. In the cerebellum PrP
res
showed a slightly faster migration (Fig. 2B). When a high
resolution gel (15%, 15 cm long) was used, the PrP
res unglycosy-
lated form in the cerebellum appeared to resolve into three bands,
which included the band corresponding to the PrP
res type 2 of
19 kDa and two additional bands that migrated about 0.5 kDa
and 1 kDa faster (Fig. 2C). The upper band containing the
diglycosylated PrP isoform was over-represented in all brain
Figure 1. Histological and immunohistochemical features. A
and B. The cerebral cortex is markedly disrupted with prominent
astrogliosis and presence of amyloid plaques (arrows in B); frontal
cortex; H.E. C and D: PrP immunostaining shows the presence of many
plaques (arrows) and plaque-like aggregates in superficial and deep
cortical regions with a punctate background staining; frontal cortex. E:
Distinctive spot-like PrP immunostaining in the molecular layer and
many plaques especially evident in the Purkinje cell layer of the
cerebellum. F: Plaques, often in a row are present in the superficial
white matter; cerebellum. C–F: Monoclonal antibody (mAb) 3F4.
doi:10.1371/journal.pone.0008765.g001
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PrP and PrP
res were best represented in the temporal cortex and
cerebellum while they were present in the least amount least
amount in the occipital cortex (Fig. 2B and E). In addition, we
confirmed the presence of a 17 kDa PrP
res fragment matching the
anchorless PrP
res type 2 fragment previously described in sporadic
CJD (sCJD) and vCJD [27], whereas the 12/13 C-terminal
fragment commonly present in sCJD was not detected (data not
shown) [28]. These two findings are in agreement with the
previously reported molecular characteristics of PrP
res from vCJD
[27]. To assess whether PrP
res types 1 and 2 co-occurred in brain
as previously reported [29], we digested the TH with a high
concentration (32 U/ml) of PK and used high resolution gels
(15%, 15 cm long), a technique that allows for the detection of
even small amounts of PrP
res type 1 and 2 (up to 3–5% of total
PrP
res) when they co-exist [30]. This procedure failed to
demonstrate PrP
res type 1 in the brain regions examined in this
case (data not shown).
Detection of PrP
res in Non-Nervous Tissues
PrP
res could be easily detected in the dura mater, the pituitary
and adrenal glands, and the uterus using direct blotting of the TH
(Table 2 and Fig. 3A and B). Detection in the skin required
doubling the TH concentration (equivalent to 4 mg of wet tissue)
but this procedure failed to reveal PrP
res in other organs (Fig. 3B,
3C, and data not shown).
With NaPTA precipitation, we easily detected PrP
res in the
mesenteric lymph nodes, spleen, ileum, pancreas, skin, and to a
lesser extent, in the descending colon, liver, ovary and kidney
(Table 2 and Fig. 3D). The unequivocal identification of PrP
res in
the kidney required multiple sampling and an additional two-fold
loading of the gel but these procedures failed to reveal PrP
res in the
ascending colon (Fig. 3C and D). Compared to direct TH blotting,
NaPTA preparations often revealed a slower electrophoretic
migration of up to 0.5 kDa (Fig. 3C, 3D and data not shown),
as previously reported [14].
A significant over-representation of the diglycosylated form with
a ratio comparable to that of the brain was apparently maintained
in all the organs except the pituitary gland, the skin and some of
the TH preparations from the uterus where diglycosylated and
monoglycosylated isoforms had nearly the same concentration
(Table 2, Fig. 3). Generally, in the NaPTA preparations the
unglycosylated form was less well represented than in the TH
preparations (Table 2, Fig. 3 and data not shown).
Figure 2. Detection and characterization of PrP
res and PK-sensitive PrP in brain. A: Immunoblot of total homogenates (TH), treated with
proteinase K (PK), obtained from the frontal cortex of sCJDMM1, sCJDMM2 (representing PrP
res types 1 and 2, respectively) and the present case
showing the over-representation of the upper band (Diglyc.) containing the diglycosylated form, and the co-migration of the lowest band (Unglyc.),
containing the unglycosylated form, with the corresponding band of sCJDMM2. B: Immunoblot of TH from the four regions of the cerebral cortex
and the cerebellum, treated with PK as indicated. The cerebellar unglycosylated PrP
res isoform generates a thicker and overall slightly faster migrating
band than the corresponding PrP
res from the cerebral cortex. C: A high-resolution immunoblot (15%, 15 cm long gel) confirms that the
monoglycosylated and unglycosylated PrP
res isoforms from the cerebellum have a faster electrophoretic mobility than the corresponding forms from
the cerebral cortex, and shows that the cerebellar unglycosylated isoform resolves into three fragments including a 19 kDa band, corresponding to
PrP
res type 2, and two additional bands of slightly lower relative molecular weight (arrowheads); T: Temporal; Cb: Cerebellum. In A–C membranes
were probed with the mAb 3F4. D and E: Ratios of the PrP
res glycoforms (D) and of the total PrP and PrP
res (E) obtained from the same brain regions
examined in panel B. Each bar represents the mean 6 SD of three densitometric determinations on each of two tissue samples.
doi:10.1371/journal.pone.0008765.g002
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revealed that in contrast to findings in the brain, most of the PK-
sensitive PrP had the electrophoretic mobility of approximately
18 kDa (after deglycosylation) in all non-neural tissues, whereas
the full length isoform appeared to be underrepresented (Fig. 4,
data not shown). This finding was particularly prominent in the
uterus but least evident in the pituitary gland (Fig. 4). Epitope
mapping indicated that the 18 kDa fragment was truncated at the
N-terminus matching the characteristics of the fragment identified
as C1 (Fig. 4) [31]. In addition to being PK-sensitive, C1 could be
easily distinguished from the unglycosylated form of PrP
res
detectable in PK untreated samples, named C2, which electro-
phoretically migrated to 19 kDa as in other organs (Fig. 4).
Discussion
Our study confirms the diagnosis of vCJD in the present case,
based on the characteristics of the PrP
res and the methionine
homozygosity at codon 129 of the PrP gene, the last feature being
invariably present in vCJD [32]. However, we also observed two
unusual features in this case. The first is the long disease duration
of 32 months, which is more than twice the 14 month mean
duration of the British cases of vCJD [3]. However, cases of up to
40 months duration after the diseases onset have been reported
[3,33]. The second unusual feature is the absence of typical
spongiform degeneration which likely stemmed from the long
duration of the disease. The long disease duration likely led to
extensive loss of neurons, in which most of the vacuoles are
formed, with ensuing astroglial scar [34].
As previously reported [21], the BSE exposure most likely
occurred between the early eighties, when the BSE epidemic
emerged in the UK, and 1992, when the patient immigrated to the
US. This assumption is consistent with an incubation period of 9
to 21 years, which correlates well with the medium incubation
period of 17 years estimated for the UK cases of vCJD [35].
The brain PrP
res of the present case displayed the glycoform
ratio and electrophoretic mobility characteristic of the PrP
res
associated with vCJD [5]. One exception is the cerebellum where
the monoglycosylated and unglycosylated PrP
res isoform migrated
slightly faster than the PrP
res from other brain regions and resolved
in three bands. The variation in PrP
res electrophoretic character-
istics between the cerebellum and the cerebral cortex is not
surprising for it has also been observed in sCJD [36]. Yet to our
knowledge it has never been reported in vCJD. Finally, contrary to
previous reports [29], PrP
res type 1 did not co-occur with type 2.
This discrepancy might stem from our rigorous PrP digestion with
PK and from the use of different antibodies, an approach that
rules out the possibility that partially cleaved fragments derived by
the incomplete digestion of PrP
Sc be misinterpreted as the type 1
fragment [30,37].
The major finding of the present study is the demonstration that
PrP
res is present in a number of non-CNS tissues and organs which
previous studies had reported as free of PrP
res (Table 1 and 2) [14–
19, P. Brown, unpublished data]. These tissues include the dura
mater, skin, liver, kidney, pancreas, descending colon, uterus and
ovary (Table 2 and Fig. 3). The use of NaPTA, along with the long
disease duration, may both have contributed to the undisputed
detection of PrP
res in these organs in this case. The glycoform ratio
of the brain PrP
res was not retained in every peripheral organ
examined (Fig. 4). In the pituitary gland and the skin the
diglycosylated and monoglycosylated PrP
res isoforms were about
equally represented thus the diglycosylated isoform was not
dominant. On the other hand, electrophoretic mobility appeared
to match that of the brain. Variations in the glycoform ratio could
be assessed only on the TH because the glycoform ratio, as well
the electrophoretic mobility, is affected by NaPTA enrichment
[14].
The presence of prion in the human dura mater is not surprising
because sCJD has been transmitted following transplantation of
dura obtained from sCJD-affected cases [38]. However, to our
knowledge this is the first immunoblot demonstration of PrP
res in
the dura mater in any prion disease. The detection of relatively
large amounts of PrP
res in the dura mater raises the possibility of
contamination with brain tissue at autopsy. Although this
possibility cannot be completely ruled out, extensive rinses in
PBS were performed before homogenization in some experiments
without observing a reduction in the amount of the PrP
res
detected.
Prion infectivity of kidney and liver has been demonstrated by
bioassay in other human prion diseases [39], and PrP
res has been
observed in the kidney of scrapie infected sheep [40]. The
presence of PrP
res has also been reported in kidney, liver and
pancreas of scrapie infected mice in association with lymphofolli-
cular proliferation [41]. This last finding is relevant to the present
case in which multiple lymphocytic infiltrates with follicular
pattern were present in the kidney. However, contrary to this
report, we observed no significant inflammatory reaction in any of
the other tissues which contained PrP
res. A puzzling finding of our
study is the presence of PrP
res albeit in small amounts in the kidney
but not in the urinary bladder. This apparent discrepancy is
relevant to the recent demonstrations of prion infectivity in urine
Table 2. Synopsis of PrP
res analyses in the brain and other
tissues.
POSITIVE
TISSUES TH
2 NaPTA
3 PrP
res4 Glyc. ratio
NEGATIVE
TISSUES
Brain ++ 100 47:33:20
Other Tissues
Dura mater
1 ++ 8.6 53:34:13 Asc. Colon
Pituitary gland ++ 5.3 40:41:19 Breast
Adrenal gland ++ 2.5 45:39:17 Diaphragm
Uterus ++ 6?10
21 50:38:13 Duodenum
Skin ++ 7?10
22 39:43:19 Esophagus
Spleen - + ,7?10
22 60:35:6 Heart
Ileum - + ,7?10
22 57:40:3 Jejunum
Mesenteric LN - + ,7?10
22 48:46:11 Left lung
Pancreas - + ,7?10
22 53:36:11 Right lung
Liver - + ,7?10
22 57:34:9 Stomach
Ovary - + ,7?10
22 58:37:5 Trachea
Descending colon
5 - + ,7?10
22 62:34:5 Urinary
bladder
Kidney - + ,7?10
22 52:35:13
1In bold italic organs where PrP
res had not been detected previously.
2TH: PrP
res searched in tissue homogenate.
3NaPTA: PrP
res searched following enrichment with sodium phosphotungstate
precipitation.
4Amount of PrP
res expressed as percentage of PrP
res present in the frontal
cortex. Glyc. ratio: glycoform ratio expressed as percentage of the sum of the
three isoforms and representing
diglycosylated:monoglycosylated:unglycosylated forms. Data listed for tissue
positive in both TH and NaPTA preparations were obtained from TH.
5PrP
res was previously reported in colon with no specification of the segment
examined.
doi:10.1371/journal.pone.0008765.t002
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diseases [42–46]. It would indicate that prion infectivity in urine is
acquired from the kidney while the urinary bladder acts as a
bystander. However the amount of PrP
res we observed in the
kidney was minimal, and might have not been sufficient to infect
the urine and to propagate to the bladder in detectable amounts.
Indeed we failed to demonstrate PrP
res in the urine in the present
case even after hundred-fold urine concentration (data not shown).
Obviously more studies are needed to clarify this issue.
The present study also demonstrates for the first time the
presence of PrP
res in the skin in a human prion disease. Previously,
PrP
res has been detected in the skin from animals with
experimental or naturally occurring scrapie [47] as well as in the
antler velvet of elk affected by CWD [48].
Furthermore, it is remarkable that we observed PrP
res in the
uterus and the ovary, a finding which implicates the reproductive
system, thereby raising the possibility of maternal transmission of
vCJD. Vertical transmissibility of prion infection has been
demonstrated in transgenic mice infected with BSE [49]. Related
literature on human prion diseases is very scanty. Pregnancy
completed to delivery has been reported in sCJD, iatrogenic CJD
and vCJD [50,51]; however, transmission to the progeny has not
been examined in detail or confirmed in any of these cases. The
first detailed determination of PrP
C and PrP
res in the reproductive
and gestational tissues from a sCJD patient has been carried out
only recently [51]. Although this study failed to detect PrP
res,
remarkably it showed that, in uterine tissue obtained at biopsy,
most of the PK-sensitive PrP is truncated at the N-terminus and
matches the C-terminal PrP
C fragment C1 which is generated
during normal PrP
C metabolism [51]. Similarly, in the present
case we observed that the C1-like fragment was largely
predominant over the full-length PrP
C in the uterus, and it was
easily digested by PK but it was present along with a significant
amount of characteristic vCJD PrP
res (Fig. 4). Since the N-
terminus of the PrP
res type 2 associated with vCJD is at residues
92–99, the uterine PrP
res must have formed from the full length
PrP
C rather than from C1, the N-terminus of which is at residues
111–112 [31,52]. These findings raise the question of the origin of
the PrP
res found in the uterus, a question that is currently
unanswered. A similar question may be raised for the urine, in
Figure 3. Detection of PrP
res in non-nervous tissues. A: PrP
res from dura mater and frontal cortex (1:24 dilution) from the present case is
compared to PrP
res of the frontal cortex from sCJDMM1 (type 1) and sCJDMM2 (type 2). B: Two film exposures of immunoblots from non-nervous
tissues compared with that of the frontal cortex (1:10 dilution). Pituitary gland, adrenal gland and uterus are clearly positive while the bands in the
remaining preparations are considered to be non specific. C: PrP
res from skin (double TH loading, equivalent to 4 mg of wet tissue) is barely
detectable in TH (Lane 3) compared with frontal cortex TH, which is diluted 1:4 (lane 1) or 1:130 (lane 2). Skin PrP
res is better detectable along with the
kidney PrP
res after sodium phosphotungstate (NaPTA) precipitation of PrP
res (Lanes 4 and 5), especially after long exposure (Lanes 4L and 5L) (kidney
TH loaded in double amount; probed with mAb 3F4). D: PrP
res from mesenteric lymph nodes and other visceral organs recovered following NaPTA
precipitation and compared with TH from the frontal cortex (1:120 dilution) and sCJDMM1 following two film exposures. All organs but ascending
colon are positive. Of note, unglycosylated isoform is underrepresented in all NaPTA precipitated samples as compared with that of the TH
preparations (see panel A, lanes 3 and 4 and panel B). A–D: Membranes were probed with the mAb 3F4.
doi:10.1371/journal.pone.0008765.g003
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animals by bioassay [42–46], the only detected form of PrP under
normal condition in animals and humans, is a fragment matching
the C1 [53, 54, Notari et al., unpublished data].
All these considerations notwithstanding, the widespread pres-
ence of PrP
res in visceral organs that we observed in the present case
further reinforces the concerns over iatrogenic transmission of
vCJD. These concerns are already compelling given the multiple
reports of vCJD transmission by blood transfusion.
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